News articles about Fibrocell Science (NASDAQ:FCSC) have trended somewhat positive this week, Accern reports. The research firm scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Fibrocell Science earned a news impact score of 0.05 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.3743442105669 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news articles that may have effected Accern Sentiment’s scoring:
- Stocks to Track: Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ), Golden Minerals Company (NYSE:AUMN), Fibrocell … (journalfinance.net)
- Fibrocell Science, Inc. (FCSC) stock price finalizes with surge of 6.60% (topdesertsafari.com)
- Fibrocell Science, Inc. (FCSC) CEO John Maslowski on Q2 2018 Results – Earnings Call Transcript (seekingalpha.com)
- Fibrocell Science (FCSC) Given a $22.00 Price Target at HC Wainwright (americanbankingnews.com)
- Fibrocell Science (FCSC) Announces Quarterly Earnings Results (americanbankingnews.com)
A number of research firms have recently issued reports on FCSC. HC Wainwright reissued a “buy” rating and issued a $22.00 price target on shares of Fibrocell Science in a research report on Tuesday, June 5th. ValuEngine upgraded Fibrocell Science from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 2nd. Finally, Zacks Investment Research upgraded Fibrocell Science from a “hold” rating to a “buy” rating and set a $3.75 price objective on the stock in a report on Tuesday, May 15th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $20.25.
Fibrocell Science (NASDAQ:FCSC) last released its quarterly earnings data on Thursday, August 9th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.50). equities analysts predict that Fibrocell Science will post -1.83 earnings per share for the current year.
Fibrocell Science Company Profile
Fibrocell Science, Inc, an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.
See Also: Trading Strategy Methods and Types
Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.